fluosol

01/01/1994 - "One pilot study suggested that intracoronary Fluosol administered at the time of reperfusion, reduced infarct size and improved regional ventricular function in patients. "
07/01/1994 - "Although Fluosol-treated patients with anterior infarction had an insignificantly lower mean infarct size (18.7% of the left ventricle) compared with patients with anterior infarction not treated with Fluosol (21.2% of left ventricle), this trend was not evident in the median infarct size values (22% versus 17%), left ventricular ejection fraction values (46% without Fluosol, 47% with Fluosol), or regional wall motion (-2.5 SD/chord in both groups). "
01/01/1992 - "These data demonstrate that low dose intravenous Fluosol produces a sustained reduction in infarct size in the canine model. "
01/01/1992 - "Fluosol significantly reduced infarct size when expressed as percent area at risk 72 h after reperfusion (13.7 +/- 2.7% vs. 38.3 +/- 4.5%, respectively, p less than 0.001). "
01/01/1992 - "The effect of a clinically tolerable dose of Fluosol on infarct size after a prolonged period of reperfusion and its mechanism of action on neutrophils remain unknown. "

10/01/1988 - "Potentiating effects were not observed when the tumors were irradiated 1-3 days after Fluosol injection, probably reflecting the observed clearance of the perfluorochemicals from the circulating blood. "
10/01/1988 - "These studies defined the effects of the Fluosol dose on the hematocrit and fluorocrit of the mice and on the radiation response of the tumors. "
01/01/1992 - "This pilot study demonstrates that Fluosol and HBO can safely be used as an adjunct to radiation in the treatment of human tumors."
10/01/1988 - "Fluosol injected 30 min-2 days before irradiation did not alter the radiation response of tumors in air-breathing or N2-asphyxiated mice. "
01/01/1985 - "BALB/c mice bearing EMT6 mouse mammary tumors were given in a single i.v. injection of 0.015 ml/g of Fluosol, and were then treated with 95% O2/5% CO2 for 30 min before irradiation with graded doses of X rays. "

07/01/1992 - "Fluosol DA 20% (Fluosol) perfusion was used to protect ischemic donor hearts of mongrel dogs from reperfusion injury. "
01/01/1994 - "To evaluate the efficacy of a perflurocarbon emulsion (Fluosol: FC-43) for protecting preserved lungs from ischemic reperfusion injuries, we employed an isolated canine left lung reperfusion model. "
07/01/1994 - "This study was performed to determine the safety and potential efficacy of an intravenous perfluorochemical emulsion (Fluosol) as an adjunct reperfusion therapy aimed at preventing reperfusion injury for patients with acute myocardial infarction. "

02/01/1990 - "It also suggests that prevention of neutrophil-mediated microvascular damage may be an important mechanism whereby Fluosol enhances myocardial salvage after ischemia and reperfusion."
03/01/1984 - "During 3 hr of ischemia intracellular pH (pHi) fell to 6.68 +/- 0.20 with STD-KCl and to 6.71 +/- 0.14 with Fluosol N2 but remained above 7.00 throughout the ischemic period with Fluosol O2 (p less than .0001 vs Fluosol N2 or STD-KCl). "
11/15/1992 - "Protection against ischemia during prolonged balloon inflation by distal coronary perfusion with use of an autoperfusion catheter or Fluosol."
11/15/1992 - "Passive (the autoperfusion balloon catheter) and active (Fluosol) distal coronary perfusion methods are comparable and better than no perfusion in protecting the myocardium against ischemia produced by prolonged coronary balloon inflation in an experimental canine model. "
07/01/1994 - "Rates of death and stroke were no different in the two groups; however, patients who received Fluosol experienced less recurrent ischemia. "

07/01/1990 - "Five patients were withdrawn prior to the institution of radiation: one patient diagnosed with bone metastasis and four patients withdrawn due to mild to moderate reactions to Fluosol. "
10/01/1988 - "Studies of tumor cell survival, tumor cell yield, tumor growth, and artificial lung metastasis formation revealed no effects of Fluosol treatment (without irradiation) on tumor progression or metastasis. "
05/01/1987 - "Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. "
01/01/1986 - "The studies reported here were undertaken as part of our laboratory evaluation of the safety and clinical potential of this oxygen-transport fluid as an adjunct to cancer therapy; they asked whether single or multiple treatments with Fluosol and an oxygen-enriched atmosphere produced immunologic perturbations, pulmonary damage, or other effects which altered the development of artificial lung metastases in experimental animals. "
01/01/2021 - "Only 2/22 agents (fluosol with oxygen, and efaproxiral) showed improvement in OS in patients with glioblastoma and brain metastasis, respectively. "